COMPARATIVE EVALUATION OF DIFFERENT REGIMEN OF PLATINUM-BASED CHEMOTHERAPY IN TREATMENT OF ADVANCED SMALL CELL LUNG CANCER (experience of chemotherapy department N.N.Blokhin Russian Cancer Research Center RAMS)


Cite item

Full Text

Abstract

The article reviews the experience of chemotherapy department N.N.Blokhin Russian Cancer Recearch Center RAMS from 1996 to 2012 in the treatment of SCLC patients with combinations of cytotoxic drugs cisplatin and carboplatin. The efficiency of different schemes on the basis of platinum with etoposide, irinotecan, docetaxel, ACNU (EP, IP, DP, AVP)has been studied. The data on the mode of treatment, side effects, and survival after these treatment schemes. Maximum efficiency was shown by EP, IP, AVP schemes.

About the authors

S. G Bagrova

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences

Email: s.bagrova@mail.ru
канд. мед. наук, науч. сотр. отд-ния химиотерапии

M. B Bychkov

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences

V. A Gorbunova

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences

A. E Kuzminov

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences

D. R Naskhletashvili

N.N.Blokhin Russian Cancer Research Center of the Russian Academy of Medical Sciences

References

  1. Evans W.K. et al. VP-16 and cisplatin as first-line therapy for SCLC. J. Clin. Oncol. 1985; 3: 1471-7.
  2. Rossi A. et al. Metaanalysis of comparison of efficiency cisplatin and carboplatin as a part of the combined chemotherapy in patients with previously untreated SCLC. J. Clin. Oncol. 2012; 70: 1692-3.
  3. Бычков М.Б. Мелкоклеточный рак легкого. В кн.: Давыдов М.И., Полоцкий Б.Е. Рак легкого. М.; 1995.
  4. Sundstrom S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in SCLC: results from a randomized phase III trial with 5 years follow-up. J. Clin. Oncol. 2002; 20: 4656-72.
  5. Hanna N., Bunn P.A. Jr., Langer C. et al. Randomized phase II trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease smallcell lung cancer. J. Clin. Oncol. 2006; 24 (13): 2038-43.
  6. Noda K., Nishiwaki Y., Kawahara M. et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive smallcell lung cancer. N. Engl. J. Med. 2002; 346 (2): 85-91.
  7. Schmittel A., Sebastian M., Fischer von Weikersthal L. et al. A German multicenter. randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann. Oncol. 2011; 22 (8): 1798-804.
  8. Насхлеташвили Д.Р. Современные возможности консервативного лечения больных с метастазами рака молочной железы и мелкоклеточного рака легкого в головной мозг: Автореф. дис.. канд. мед. наук. М.; 2002.
  9. Ettinger D.S., Finkelscein D.M., Sarma R.P. et al. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: An Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 1995; 13: 1430-5.
  10. Jett J.R., Kirschling R.J., Jung S.H. et al. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer. A study of the North Central Cancer Treatment Group. Semin. Oncol. 1995; 22 (Suppl. 6): 75-7.
  11. Hesketh P.J., Crowley J., Burris H.A. et al. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group phase II trial. Cancer J. Sci. Am. 1999; 5: 237-41.
  12. Кузьминов А.Е. Разработка новых режимов химиотерапии диссеминированного мелкоклеточного рака легкого: Автореф. дис. канд. мед. наук. М.; 2007.

Copyright (c) 2013 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies